|
|
|
Insider
Information: |
Shah Rajeev M. |
Relationship: |
10% Owner |
City: |
Boston |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
49 |
|
Direct
Shares |
20,000 |
|
Indirect Shares
|
279,677,593 |
|
|
Direct
Value |
$135,400 |
|
|
Indirect Value
|
$1,665,776,883 |
|
|
Total
Shares |
279,697,593 |
|
|
Total
Value |
$1,665,912,283 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
40
|
13
|
Stock
price went up :
|
20
|
8
|
Stock
price went down : |
20
|
5
|
|
|
|
Gain/Loss Ratio : |
0.0
|
1.6
|
Percentage
Gain/Loss : |
10.4%
|
-60.6%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Ra Pharmaceuticals, Inc. |
RARX |
Director, 10% Owner |
2016-10-31 |
0 |
2020-04-02 |
0 |
Premium* |
|
Kalvista Pharmaceuticals Inc |
KALV |
Director, 10% Owner |
2016-11-21 |
0 |
2017-10-12 |
1,441,070 |
Premium* |
|
Kala Pharmaceuticals, Inc. |
KALA |
10% Owner |
2021-06-17 |
20,000 |
2022-05-26 |
7,039,613 |
Premium* |
|
Solid Biosciences Inc |
SLDB |
Director, 10% Owner |
2018-01-30 |
0 |
2022-12-02 |
109,661 |
Premium* |
|
Eidos Therapeutics, Inc. |
EIDX |
Director |
2018-06-22 |
0 |
2018-06-22 |
2,162,671 |
Premium* |
|
Satsuma Pharmaceuticals, Inc. |
STSA |
Director, 10% Owner |
2019-09-17 |
0 |
2023-06-06 |
0 |
Premium* |
|
Phathom Pharmaceuticals, Inc. |
PHAT |
10% Owner |
|
0 |
2021-03-11 |
3,115,008 |
Premium* |
|
89bio, Inc. |
ETNB |
Director, 10% Owner |
2019-11-11 |
0 |
2024-04-11 |
14,175,398 |
Premium* |
|
Synthorx, Inc. |
THOR |
10% Owner |
2020-01-23 |
0 |
2020-01-23 |
0 |
Premium* |
|
Black Diamond Therapeutics, Inc. |
BDTX |
Director |
2021-05-20 |
0 |
2023-07-05 |
3,525,754 |
Premium* |
|
Scpharmaceuticals Inc. |
SCPH |
10% Owner |
2020-02-14 |
0 |
2021-03-15 |
2,727,446 |
Premium* |
|
Verastem, Inc. |
VSTM |
10% Owner |
|
0 |
2020-06-25 |
16,142,051 |
Premium* |
|
Enliven Therapeutics Ord Shs |
ELVN |
Former 10% owner |
2020-03-16 |
0 |
2023-02-23 |
2,122,465 |
Premium* |
|
TG Therapeutics Inc |
TGTX |
10% Owner |
|
0 |
2020-09-09 |
12,629,868 |
Premium* |
|
Vaxcyte, Inc. |
PCVX |
10% Owner |
|
0 |
2020-10-08 |
5,001,593 |
Premium* |
|
Forma Therapeutics Holdings, Inc., |
FMTX |
10% Owner |
2020-06-23 |
0 |
2022-10-14 |
0 |
Premium* |
|
Rhythm Pharmaceuticals, Inc. |
RYTM |
10% Owner |
2020-06-25 |
0 |
2020-07-02 |
5,140,408 |
Premium* |
|
Akouos, Inc. |
AKUS |
10% Owner |
2020-06-30 |
0 |
2020-06-30 |
2,281,249 |
Premium* |
|
Nkarta, Inc. |
NKTX |
Director, 10% Owner |
2020-07-14 |
0 |
2024-03-27 |
10,805,129 |
Premium* |
|
Pandion Therapeutics, Inc. |
PAND |
10% Owner |
2020-07-21 |
0 |
2020-07-21 |
1,770,023 |
Premium* |
|
Inozyme Pharma, Inc. |
INZY |
10% Owner |
2020-07-28 |
0 |
2020-07-28 |
2,003,653 |
Premium* |
|
Iteos Therapeutics, Inc. |
ITOS |
Former 10% Owner |
2020-07-28 |
0 |
2024-05-12 |
3,517,259 |
Premium* |
|
Inhibrx, Inc. |
INBX |
10% Owner |
2020-08-21 |
0 |
2020-08-21 |
2,129,003 |
Premium* |
|
Dyne Therapeutics, Inc. |
DYN |
10% Owner |
2020-09-21 |
0 |
2020-09-21 |
2,805,045 |
Premium* |
|
Pmv Pharmaceuticals, Inc. |
PMVP |
10% Owner |
2020-09-29 |
0 |
2020-09-29 |
1,710,265 |
Premium* |
|
Cardiff Oncology Inc |
CRDF |
10% Owner |
|
0 |
2020-09-30 |
3,290,000 |
Premium* |
|
Orchard Therapeutics Plc |
ORTX |
10% Owner |
2020-08-10 |
0 |
2020-09-24 |
9,880,865 |
Premium* |
|
Viridian Therapeutics Ors Shs |
VRDN |
10% Owner |
|
0 |
2020-12-07 |
410,686 |
Premium* |
|
Iterum Therapeutics Plc |
ITRM |
10% Owner |
2021-02-04 |
0 |
2021-02-04 |
11,651,597 |
Premium* |
|
Vor Biopharma Inc. |
VOR |
Director, 10% Owner |
2021-02-09 |
0 |
2022-12-09 |
22,748,880 |
Premium* |
|
Werewolf Therapeutics, Inc. |
HOWL |
Director, 10% Owner |
2021-05-04 |
0 |
2023-01-06 |
6,144,881 |
Premium* |
|
Aerovate Therapeutics, Inc. |
AVTE |
Director, 10% Owner |
2021-07-02 |
0 |
2021-07-02 |
311,170 |
Premium* |
|
Acumen Pharmaceuticals, Inc. |
ABOS |
Director, 10% Owner |
2021-07-06 |
0 |
2023-07-21 |
14,932,063 |
Premium* |
|
Cytek Biosciences, Inc. |
CTKB |
Director, 10% Owner |
2021-07-27 |
0 |
2022-03-15 |
13,381,054 |
Premium* |
|
Icosavax, Inc. |
ICVX |
Director, 10% Owner |
2021-08-02 |
0 |
2024-02-19 |
0 |
Premium* |
|
Eliem Therapeutics, Inc. |
ELYM |
Director, 10% Owner |
|
0 |
2021-08-12 |
841,087 |
Premium* |
|
Rxsight, Inc. |
RXST |
10% Owner |
|
0 |
2021-08-03 |
3,052,796 |
Premium* |
|
Tyra Biosciences, Inc. |
TYRA |
Director, 10% Owner |
2021-09-17 |
0 |
2024-02-06 |
10,416,609 |
Premium* |
|
Dice Therapeutics, Inc. |
DICE |
Former 10% owners and ... |
2021-09-17 |
0 |
2023-08-09 |
0 |
Premium* |
|
An2 Therapeutics Ord Shs |
ANTX |
10% Owner |
2022-03-29 |
0 |
2023-08-18 |
5,551,295 |
Premium* |
|
Pepgen Inc. |
PEPG |
Director, 10% Owner |
2022-05-10 |
0 |
2024-02-09 |
10,689,545 |
Premium* |
|
Wave Life Sciences Ltd. |
WVE |
Director, 10% Owner |
2022-06-16 |
0 |
2023-12-11 |
18,202,009 |
Premium* |
|
Fulcrum Therapeutics, Inc. |
FULC |
10% Owner |
|
0 |
2023-01-20 |
11,609,704 |
Premium* |
|
Silverback Therapeutics, Inc. |
SBTX |
Director, 10% Owner |
2022-11-08 |
0 |
2024-03-27 |
10,860,977 |
Premium* |
|
Acrivon Therapeutics, Inc. |
ACRV |
Director, 10% Owner |
2022-11-17 |
0 |
2024-04-11 |
8,340,508 |
Premium* |
|
Mineralys Therapeutics, Inc. |
MLYS |
Director |
2023-02-14 |
0 |
2024-02-12 |
4,850,984 |
Premium* |
|
Janux Therapeutics, Inc. |
JANX |
Director, 10% Owner |
2023-07-19 |
0 |
2023-07-19 |
9,165,652 |
Premium* |
|
Lenz Therapeutics |
LENZ |
Director, 10% Owner |
2024-03-21 |
0 |
2024-03-21 |
694,755 |
Premium* |
|
Boundless Bio, Inc. |
BOLD |
10% Owner |
2024-04-02 |
0 |
2024-04-02 |
295,844 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
216 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 6 of 9
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
CTKB |
Cytek Biosciences, Inc. |
Director |
|
2022-03-02 |
4 |
AB |
$12.89 |
$1,782,218 |
I/I |
138,255 |
11,515,282 |
0 |
% |
|
CTKB |
Cytek Biosciences, Inc. |
Director |
|
2022-03-04 |
4 |
AB |
$12.99 |
$827,230 |
I/I |
63,662 |
11,578,944 |
0 |
% |
|
CTKB |
Cytek Biosciences, Inc. |
Director |
|
2022-03-07 |
4 |
AB |
$12.61 |
$4,260,965 |
I/I |
337,901 |
11,916,845 |
0 |
% |
|
CTKB |
Cytek Biosciences, Inc. |
Director |
|
2022-03-08 |
4 |
AB |
$12.86 |
$3,160,059 |
I/I |
245,701 |
12,162,546 |
0 |
% |
|
CTKB |
Cytek Biosciences, Inc. |
Director |
|
2022-03-09 |
4 |
AB |
$12.99 |
$521,753 |
I/I |
40,154 |
12,202,700 |
0 |
% |
|
CTKB |
Cytek Biosciences, Inc. |
Director |
|
2022-03-10 |
4 |
AB |
$12.95 |
$3,327,584 |
I/I |
256,992 |
12,459,692 |
0 |
% |
|
CTKB |
Cytek Biosciences, Inc. |
Director |
|
2022-03-11 |
4 |
AB |
$12.77 |
$4,309,334 |
I/I |
337,492 |
12,797,184 |
0 |
% |
|
CTKB |
Cytek Biosciences, Inc. |
Director |
|
2022-03-14 |
4 |
AB |
$12.35 |
$4,223,926 |
I/I |
342,143 |
13,139,327 |
0 |
% |
|
CTKB |
Cytek Biosciences, Inc. |
Director |
|
2022-03-15 |
4 |
AB |
$12.27 |
$2,964,999 |
I/I |
241,727 |
13,381,054 |
0 |
% |
|
ICVX |
Icosavax, Inc. |
Director |
|
2022-03-28 |
4 |
B |
$4.53 |
$794,611 |
I/I |
175,318 |
5,953,665 |
2.25 |
- |
|
ICVX |
Icosavax, Inc. |
Director |
|
2022-03-29 |
4 |
B |
$4.75 |
$42,271 |
I/I |
8,900 |
5,963,565 |
2.25 |
- |
|
ANTX |
An2 Therapeutics Ord Shs |
10% Owner |
|
2022-03-29 |
4 |
A |
$0.00 |
$0 |
I/I |
1,999,997 |
299,999 |
0 |
- |
|
ANTX |
An2 Therapeutics Ord Shs |
10% Owner |
|
2022-03-29 |
4 |
B |
$15.00 |
$24,999,990 |
I/I |
1,666,666 |
415,612 |
1.5 |
% |
|
NKTX |
Nkarta, Inc. |
Director |
|
2022-04-26 |
4 |
B |
$15.00 |
$33,000,000 |
I/I |
2,200,000 |
7,805,129 |
2.25 |
- |
|
PEPG |
Pepgen Inc. |
Director |
|
2022-05-10 |
4 |
A |
$0.00 |
$0 |
I/I |
4,902,752 |
207,672 |
0 |
- |
|
PEPG |
Pepgen Inc. |
Director |
|
2022-05-10 |
4 |
B |
$12.00 |
$38,750,400 |
I/I |
3,229,200 |
1,302,600 |
2.25 |
% |
|
KALA |
Kala Pharmaceuticals, Inc... |
10% Owner |
|
2022-05-23 |
4 |
S |
$0.65 |
$812,500 |
I/I |
(1,250,000) |
9,624,613 |
0 |
% |
|
KALA |
Kala Pharmaceuticals, Inc... |
10% Owner |
|
2022-05-24 |
4 |
S |
$0.51 |
$73,851 |
I/I |
(144,805) |
9,479,808 |
0 |
% |
|
KALA |
Kala Pharmaceuticals, Inc... |
10% Owner |
|
2022-05-25 |
4 |
S |
$0.42 |
$602,494 |
I/I |
(1,434,509) |
8,045,299 |
0 |
% |
|
KALA |
Kala Pharmaceuticals, Inc... |
10% Owner |
|
2022-05-26 |
4 |
S |
$0.36 |
$365,667 |
I/I |
(1,005,686) |
7,039,613 |
0 |
% |
|
ANTX |
An2 Therapeutics Ord Shs |
10% Owner |
|
2022-06-13 |
4 |
B |
$7.90 |
$158,000 |
I/I |
20,000 |
3,686,663 |
1.5 |
% |
|
ANTX |
An2 Therapeutics Ord Shs |
10% Owner |
|
2022-06-14 |
4 |
B |
$7.97 |
$489,402 |
I/I |
61,424 |
3,748,087 |
1.5 |
% |
|
WVE |
Wave Life Sciences Ltd. |
Director |
|
2022-06-16 |
4 |
B |
$2.15 |
$20,382,112 |
I/I |
9,480,052 |
17,202,009 |
2.25 |
% |
|
ANTX |
An2 Therapeutics Ord Shs |
10% Owner |
|
2022-06-21 |
4 |
B |
$7.99 |
$2,413 |
I/I |
302 |
3,748,389 |
1.42 |
% |
|
ETNB |
89bio, Inc. |
Director |
|
2022-07-01 |
4 |
B |
$3.55 |
$9,999,995 |
I/I |
2,816,900 |
7,782,669 |
2.25 |
% |
|
216 Records found
|
|
Page 6 of 9 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|